Clinical trials: Coronavirus Disease-2019
COVID-19
Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19)
Participants will be randomized in a 1:1 ratio to receive Colchicine plus current care per UCLA treating physicians versus current care per UCLA treating physicians alone (control arm).
- Trial name
- COLHEART-19 (NCT04355143)
- Testing
- Colchicine Tablets, Current care per UCLA treating physicians
- Where
- 3 sites in United States
- Volunteers
- 93 people
- Sponsor
- University of California, Los Angeles
COVID-19
Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19), is associated with a high incidence of acute respiratory distress syndrome (ARDS) and death.
- Trial name
- REPLACECOVID (NCT04338009)
- Testing
- Discontinuation of ARB/ACEI, Continuation of ARB/ACEI
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- University of Pennsylvania
COVID, Corona Virus Infection
Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation
The purpose of this study is to examine the impact of ascorbic acid (vitamin c) and zinc gluconate in reducing duration of symptoms in patients diagnosed with coronavirus disease 2019 (COVID-19).
- Trial name
- COVIDAtoZ (NCT04342728)
- Testing
- Ascorbic Acid, Zinc Gluconate, Ascorbic Acid and Zinc Gluconate
- Where
- 2 sites in United States
- Volunteers
- 214 people
- Sponsor
- The Cleveland Clinic
Covid19
Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19
Study into the effects of daily use of metformin and low-dose naltrexone (LDN) for 4 weeks to reduce symptoms, disease severity, and recovery time from COVID-19.
- Trial name
- NCT04604678
- Testing
- Metformin, Naltrexone
- Where
- United States
- Sponsor
- AgelessRx
Coronavirus Disease 2019
Humanistic Care in Healthcare Workers in Coronavirus Disease 2019
As of February 17th, 2020, China has 76396 confirmed cases of coronavirus disease 2019 (COVID-19), including 2348 deaths. The impact factors of clinical outcomes among hospitalized patients still need to be clarified.
- Trial name
- NCT04283838
- Testing
- Humanistic Care
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis
Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT
Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, and Coronavirus Disease 2019 with [18F]FP-R01-MG-F2 with PET/CT
- Conditions
- Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, Covid19 Pneumonia
- Trial name
- NCT03183570
- Testing
- [18F]FP-R01-MG-F2
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Stanford University
COVID-19
A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine
This is a medical study where participants will be randomly assigned to receive either a new combination vaccine that protects against both COVID-19 and the flu, or a standard flu vaccine.
- Trial name
- NCT06291857
- Testing
- CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant, Novavax COVID-19 Vaccine, tNIV Vaccine
- Where
- 58 sites in Australia, New Zealand
- Volunteers
- 9,320 people, healthy volunteers welcome
- Sponsor
- Novavax
COVID-19 Vaccine
ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine
The goals of this clinical trial are: 1. Phase 2: to test a gamma adapted recombinant vaccine against SARS-CoV-2 in healthy adult volunteers, previously vaccinated against the SARS-CoV-2 virus. 2.
- Trial name
- ARVAC-F2/3 (NCT05752201)
- Testing
- Gamma Variant RBD-based ARVAC-CG vaccine, Omicron Variant RBD-based ARVAC-CG vaccine, Bivalent RBD-based ARVAC-CG vaccine
- Where
- 11 sites in Argentina
- Volunteers
- 2,014 people, healthy volunteers welcome
- Sponsor
- Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno
Healthy Participant
A Study to Learn How the Study Medicine Called Ibuzatrelvir is Taken up Into the Blood in Healthy Chinese Adults
A study to learn how the study medicine called Ibuzatrelvir is taken up into the blood in healthy Chinese adults.
- Trial name
- NCT07235137
- Testing
- Ibuzatrelvir
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19, SARS CoV 2 Infection
STREngthening COronavirus Disease 2019 (COVID-19) Surveillance in Africa
The aim of this observational study was to develop, with the intended users, an epidemic surveillance and response system that will be effective, sensitive, coordinated and appropriate.
- Conditions
- COVID-19, SARS CoV 2 Infection, COVID-19 Pandemic
- Trial name
- STREESCO (NCT06170320)
- Where
- Benin
- Volunteers
- 7,000 people
- Sponsor
- Institut de Recherche pour le Developpement
COVID-19, Protection Against COVID-19 and Infections With SARS-CoV- 2
Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers
This is a multicentre, open-label Phase 1/2 study, with a first-in-human (FIH) dose escalation part (Phase 1 study) followed by an open-label single arm (or two-arms, randomized) dose expansion part (Phase 2 study).
- Conditions
- COVID-19, Protection Against COVID-19 and Infections With SARS-CoV- 2, COVID-19 Immunisation
- Trial name
- NCT04788459
- Testing
- COVID-eVax, Cliniporator® and EPSGun
- Where
- 4 sites in Italy
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Takis
Hypertension, COVID-19
Coronavirus (COVID-19) ACEi/ARB Investigation
Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by a virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- CORONACION (NCT04330300)
- Testing
- Thiazide or Thiazide-like diuretics, Calcium Channel Blockers, ACE inhibitor
- Where
- Ireland
- Volunteers
- 2,414 people
- Sponsor
- National University of Ireland, Galway, Ireland
Coronavirus Disease 2019 (COVID-19), SARS-CoV-2
Immunophenotyping Assessment in a COVID-19 Cohort
This surveillance study will collect detailed clinical, laboratory, and radiographic data in coordination with biologic sampling of blood and respiratory secretions and viral shedding in nasal secretions in order to identify…
- Trial name
- IMPACC (NCT04378777)
- Testing
- Biological sample collection, Data Collection: Clinical Care Assessments
- Where
- 17 sites in United States
- Volunteers
- 1,227 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Coronavirus Infectious Disease 2019 (COVID-19)
COVID-19 in Baselland: Validation of Simple and Accurate Tests for COVID-19 Detection, Monitoring and Tracing (ACCURATE-BL-COVID-19)
This study is to establish an accurate, robust and easily scalable COVID-19 viral nucleic acid analysis platform from, but not limited to, saliva to help enable and support contact tracing in the canton of Baselland/ Switzerland.
- Trial name
- NCT04625257
- Testing
- Saliva based assay: crude RNA extraction, Validation of the NGS method, Validation of the LAMP assays
- Where
- Switzerland
- Volunteers
- 1,600 people
- Sponsor
- University Hospital, Basel, Switzerland
COVID-19
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19
This study will evaluate the efficacy, safety, antiviral activity, and pharmacokinetics of study drug RO7496998 (AT-527) compared to placebo in non-hospitalized adult and adolescent participants with mild to moderate coronavirus…
- Trial name
- MORNINGSKY (NCT04889040)
- Testing
- RO7496998
- Where
- 50 sites in Argentina, Belgium and 10 more
- Volunteers
- 216 people
- Sponsor
- Hoffmann-La Roche
Coronavirus Disease 2019 (COVID-19)
Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19)
Coronavirus Disease 2019 (COVID-19) is spreading worldwide and has become a public health emergency of major international concern. Currently, no specific drugs or vaccines are available.
- Trial name
- NCT04346368
- Testing
- BM-MSCs
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Covid19, SARS-CoV2 Infection
Masitinib in Patients With Symptomatic Mild to Moderate COVID-19
The objective of the study is to evaluate the anti-viral efficacy of 3 different dosages of masitinib in patients with symptomatic mild to moderate COVID-19.
- Conditions
- Covid19, SARS-CoV2 Infection, Coronavirus Disease 2019
- Trial name
- NCT05047783
- Testing
- Masitinib Mesylate
- Where
- 6 sites in France, Russia and 1 more
- Volunteers
- 78 people
- Sponsor
- AB Science
Coronavirus Disease 2019, Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
Study of Varespladib in Patients Hospitalized With Severe COVID-19
This is a 2-part, multi-center, randomized, double-blind, placebo-controlled, phase 2 study designed to evaluate the safety, tolerability, and efficacy of oral varespladib, in addition to standard of care, in patients…
- Trial name
- STAIRS (NCT04969991)
- Testing
- Varespladib
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Ophirex, Inc.
SARS-CoV-2 Infection
A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults
The primary objectives of this open-label trial were to evaluate the safety and pharmacokinetics (PK) of Anti-SARS-CoV-2 Immunoglobulin (Human) Investigational Product (COVID-HIG) administered intramuscularly (IM), subcutaneously…
- Trial name
- NCT05142306
- Testing
- COVID-HIG
- Where
- 2 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Coronavirus
Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19)
This multi-center, open-label, 2 arm parallel-group, randomized, interventional prospective exploratory study in 40 patients aimed to evaluate safety and explore putative clinical benefits of Silmitasertib 1000 mg BID dose in…
- Trial name
- CX4945 (NCT04668209)
- Testing
- Silmitasertib
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- University of Arizona